With all the new names pretending to be new sheep are basically all the same old fleeced bag holders. Really very amusing to say the least.
Come on now you old secluded investors fess up and come clean.
Sentiment: Strong Sell
RISKS RELATED TO OUR BUSINESS
Risks Related to Our Capital Requirements, Finances and Operations
We have incurred losses since our inception, we expect our operating expenses to continue to exceed our revenue for the foreseeable future, and we may never generate revenue sufficient to achieve profitability.
We are a development-stage company and have not generated sustainable revenue from operations or been profitable since inception, and we may never achieve profitability. We have devoted our resources to acquiring and developing proprietary product candidates, but such product candidates cannot be marketed until the regulatory process is completed and governmental approvals have been obtained. We have accumulated net losses totaling approximately $192.8 million as of March 31, 2013, and we expect to continue to incur substantial operating losses for the next several years .....
Sentiment: Strong Sell
Mast Therapeutics (MSTX) focuses on developing therapies for serious or life-threatening diseases. Its lead product candidate includes MST-188, a product candidate that has hemorheologic, cytoprotective, and anti-inflammatory properties, which is in phase 3 study for the treatment of sickle cell disease in patients. I rarely cover stocks that sell for less than $1 a share, but I will make an exception for this speculative biotech play.
One very interesting thing about Mast is that its entire market capitalization is represented by the net cash on its balance sheet after a recent secondary offering. The other thing that caught my eye on this stock was a report from Canaccord Genuity this week on this fifty cent a share stock. The analyst firm initiated the shares with a whopping $3 a share price target. Its analyst noted "We think MST-188 could gain significant market share given the unmet need in SCD and potential combo-Tx. Our $3.00 target is based on NPV analysis."
This is a speculative play for patient long term investors. Even Canaccord's analyst does not see a launch of MST-188 until 2017, although he also puts eventual peak sales at $400mm annually. Only three analysts cover this ~$50mm market capitalization concern. Their price targets range from $1 to $3 a share.
Sentiment: Strong Buy